In the 20th Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 21 075 new patients and 40 769 previously followed patients were compiled from 544 institutions over a 2-year period from 1 January 2008 to 31 December 2009. Compared with the previous 19th survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, included more female patients, included more patients with non-B non-C HCC, had smaller tumor diameters and more frequently received radiofrequency ablation as local ablation therapy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and by background characteristics for patients newly registered between 1998 and 2009 whose final outcome was survival or death. Cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, and Child-Pugh grade) and by treatment types (hepatectomy, local ablation therapy, and transcatheter arterial chemoembolization). Cumulative survival rates and median overall survival in patients treated by resection, transcatheter arterial chemoembolization, and local ablation therapy were calculated. The same values were also calculated by the registration date by dividing patients newly registered between 1978 and 2009 into four time period groups . The results of the analysis show that the prognosis of HCC is improving dramatically. It is expected that the data obtained from this nationwide follow-up survey will contribute to advancing clinical research, including the design of clinical trials, as well as the treatment strategy of primary liver cancer in the clinical practice setting.
INTRODUCTION
T HE LIVER CANCER Study Group of Japan has worked to advance the study and treatment of liver cancer since 1969, carrying out 19 national surveys on primary liver cancer with institutional members and collaborating institutions across Japan based on its General Rules for the Clinical and Pathological Study of Primary Liver Cancer, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] and publishing the official results of those surveys and original article using this database. The group also reports on the Response Evaluation Criteria in Cancer of the Liver. [71] [72] [73] [74] [75] This report presents the results of the 20th Nationwide Follow-up Survey of Primary Liver Cancer in Japan, with data obtained for 21 075 newly registered patients attending 544 institutions across Japan over the 2-year period from 1 January 2008 to 31 December 2009 . The valid response rate for the 40 769 previously followed patients was 90.4%. Epidemiological, clinicopathological, diagnostic, and treatment-related data were compiled for newly registered patients. Cumulative survival rates by histological type, background characteristics, and treatments were also calculated for patients newly registered in the 15th to 20th surveys during 1978 to 2009. This special report is a concise version of the original full-version report published in Japanese. 41, 76 
METHODS

Basic statistics
T HE PARTICIPANTS OF this survey were patients who were hospitalized, underwent outpatient treatment, or underwent autopsy for primary liver cancer at each Table 2 Prognosis Table 3 Past medical history For all parameters, n is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of n. F0, no fibrosis; F1, fibrous expansion of portal tract; F2, fibrous septa formation, usually incomplete; F3, bridging fibrous formation accompanying lobular distortion A0, no necroinflammatory reaction; A1, mild necroinflammatory reaction; A2, moderate necroinflammatory reaction; A3, severe necroinflammatory reaction; SVR; sustained viral response. 
Cumulative survival
Cumulative survival rates were calculated for HCC, ICC, and combined HCC and ICC by treatments and by background characteristics for patients newly registered between 1998 and 2009 whose final outcome was survival or death (excluding unknown). Cumulative survival rates for HCC were calculated by treatments (hepatectomy, local ablation therapy, and transcatheter arterial chemoembolization [TACE]). Cumulative survival rates were also calculated by the registration date by dividing patients newly registered between 1978 and 2009 into four time period groups. These cumulative survival rate calculations were made without censoring any deaths, including those in the "Other" category.
RESULTS
Basic statistics
Causes of death of newly enrolled patients during the survey period
The mortality rate during the survey period for newly enrolled patients with HCC was 17.2% (3396 patients). The cause of death was cancer for 62.5%, liver failure for 16.0%, gastrointestinal hemorrhage for 1.4%, and rupture of esophageal or gastric varices for 2.4%. The mortality rate from surgery among the patients who underwent surgery was 0.9% (30 patients). The mortality rate for newly enrolled patients with ICC was 30.0% (302 patients). The cause of death was cancer for 85.4% and liver failure for 4.3% (Table 2) . (Table 4 ). In HCC, serum αfetoprotein was <15 ng/mL in 46.4%, 15-199 ng/mL in 31.1%, and ≥ 200 ng/mL in 22.5% of patients. lectinreactive α-fetoprotein was <10% in 68.3%, 10-14.9% in 4.1%, and ≥15% in 27.6% of patients. Protein induced by vitamin K absence or antagonist-II was <40 mAU/mL in 39.5%, 40-99 mAU/mL in 15.4%, and ≥100 mAU/mL in 45.1% of patients. In ICC, CEA was <5.0 ng/mL in 63.5%, 5.0-9.9 ng/mL in 14.8%, and ≥10 ng/mL in 21.7% of patients. CA19-9 was <37 U/mL in 37.9%, 37-99 U/mL in 13.3%, and ≥ 100 U/mL in 48.8% of patients ( (Table 6 ). Tumor staining was observed in 93.1%, tumor rupture in 0.9%, and F2 or larger/red color sign (+) esophageal or gastric varices in 35.8% of patients.
Initial treatments
The initial treatment method for HCC was surgical intervention (resection or transplantation) in 37.7%, local ablation therapy in 28.4%, and TACE in 27.5% of patients. For ICC, these figures were 72.9% for surgery (resection only) and 16.6% for systemic chemotherapy, and for combined HCC and ICC, they were 71.8% for surgery (hepatectomy only) and 4.2% for systemic chemotherapy ( Table 7 ). The distribution of Child-Pugh grades (A/B/C) was 78.4%/20.3%/1.3% for those who underwent surgery, 69.2%/27.4%/3.3% for those who underwent local ablation therapy, and 59.7%/35.8%/ 4.4% for those who underwent TACE.
Surgery
A total of 6940 patients with HCC underwent hepatectomy and 122 underwent liver transplantation. The most common macroscopic classification of resected specimens was simple nodular type for HCC at 59.9% and mass-forming type for ICC at 76.4% (Tables 8, 9) .
Tumor diameter among patients who underwent hepatectomy for HCC was ≤2 cm in 20.0%, 2-5 cm in 52.0%, and 5-10 cm in 20.3%. The percentage with unifocal disease was 75.9%. Vascular invasion was observed in the portal vein in 16.1%, hepatic For all parameters, n is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of n.
HBcAb, antibody to hepatitis B core antigen; HBeAb, antibody to hepatitis B e antigen; HBeAg, hepatitis B e antigen; HBsAb, antibody to hepatitis B surface antigen; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus. (Table 10) . Among patients with ICC, tumor diameter was ≤2 cm in 12.6%, 2-5 cm in 53.4%, and 5-10 cm in 28.1% of patients, and 84.9% had unifocal disease. For all parameters, n is the total number of patients excluding those in the "unknown" category, and (%) is the percentage of n. B 0 , absence of invasion of the bile ducts; B 1 , invasion of (or tumor thrombus in) the third order or more peripheral branches of the bile duct, but not of second order branches; B 2 , invasion of (or tumor thrombus in) the second order branches of the bile duct; B 3 , invasion of (or tumor thrombus in) the first order branches of the bile duct; B 4 , invasion of (or tumor thrombus in) the common hepatic duct.; F1, small varices; F2, moderate varices; RC, red color sign; Vp0, absence of invasion of (or tumor thrombus in) the portal vein; Vp 1 , invasion of (or tumor thrombus in) distal to the second order branches of the portal vein, but not of the second order branches; Vp 2 , invasion of (or tumor thrombus in) second order branches of the portal vein; Vp 3 , invasion of (or tumor thrombus in) first order branches of the portal vein; Vp 4 , invasion of (or tumor thrombus in) the main trunk of the portal vein and/or contra-lateral portal vein branch to the primarily involved lobe; Vv 0 , absence of invasion of (or tumor thrombus in) the hepatic vein; Vv 1 , invasion of (or tumor thrombus in) peripheral branches of the hepatic vein; Vv 2 , invasion of (or tumor thrombus in) the right, middle, or left hepatic vein, the inferior right hepatic vein, or the short hepatic vein; Vv 3 , invasion of (or tumor thrombus in) the inferior vena cava.
Local ablation therapy
Local ablation therapy was performed in 6174 patients with HCC. Percutaneous ethanol injection therapy was performed in 7.4%, percutaneous microwave coagulation therapy in 3.2%, and radiofrequency ablation in 81.5% (Table 11 ). The treatment route was percutaneous for 88.8%. The percentage with unifocal disease was 89.2%. Tumor diameter was ≤2 cm in 64.6% and 2-3 cm in 26.2% of patients. The response assessed at (Table 12 ). In addition, 93.6% of patients For all parameters, n is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of n. B 0 , absence of invasion of the bile ducts; B 1 , invasion of (or tumor thrombus in) the third order or more peripheral branches of the bile duct, but not of second order branches; B 2 , invasion of (or tumor thrombus in) the second order branches of the bile duct; B 3 , invasion of (or tumor thrombus in) the first order branches of the bile duct; B 4 , invasion of (or tumor thrombus in) the common hepatic duct; Eg, expansive growth, welldemarcated border; Fc (À), absence of capsule formation; Fc (+), presence of capsule formation; Fc-Inf (À), absence of cancerous infiltration of the tumor capsule; Fc-Inf (+), presence of cancerous infiltration of the tumor capsule; H1, cancer limited to one segment; H2, cancer limited to two segments; H3, cancer limited to three segments; H4, cancer involving more than three segments; Hr0, resection of less than one subsegment (Couinaud's segment); HrS, resection of one subsegment (Couinaud's segment); Hr1, resection of one segment (anterior, posterior, medial, or left lateral segmentectomy); Hr2, resection of two segments (right or left bisegmentectomy or central bisegmentectomy); Hr3, resection of three segments (right or left trisegmentectomy); Hs, cancer limited to one subsegment, poorly demarcated border; Ig, infiltrative growth; IM 0 , absence of intrahepatic metastasis; IM 1 , intrahepatic metastasis within the subsegment in which the principal tumor is located; IM 2 , intrahepatic metastasis in two segments; IM 3 , intrahepatic metastasis to three or more segments; IM s , intrahepatic metastasis within the subsegment in which the principal tumor is located; LCSGJ, Liver Cancer Study Group of Japan; S0, absence of invasion of the serosa; S1, tumor invasion of the serosa; S2, tumor invasion of adjacent organs; S3, tumor rupture with intraperitoneal bleeding; Sf (À), absence of formation of a fibrous septum within the tumor; Sf (+), presence of fibrous septum within the tumor; TNM, tumor-node-metastasis; Va 0 , absence of invasion of the hepatic artery; Va 1 , invasion distal to the second order branches of the hepatic artery, but not of the second order branches; Va 2 , invasion to the second order branches of the hepatic artery; Va 3 , invasion to the left or right hepatic artery, or the proper hepatic artery; Vp 0 , absence of invasion of (or tumor thrombus in) the portal vein; Vp 1 , invasion of (or tumor thrombus in) distal to the second order branches of the portal vein, but not of the second order branches; Vp 2 , invasion of (or tumor thrombus in) second order branches of the portal vein; Vp 3 , invasion of (or tumor thrombus in) first order branches of the portal vein; Vp 4 , invasion of (or tumor thrombus in) the main trunk of the portal vein and/or contra-lateral portal vein branch to the primarily involved lobe; Vv 0 , absence of invasion of (or tumor thrombus in) the hepatic vein; Vv 1 , invasion of (or tumor thrombus in) peripheral branches of the hepatic vein; Vv 2 , invasion of (or tumor thrombus in) the right, middle, or left hepatic vein, the inferior right hepatic vein, or the short hepatic vein; Vv 3 , invasion of (or tumor thrombus in) the inferior vena cava. Table 11 Local ablation therapy For all parameters, n is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of n. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; TE2, treatment effect in target lesion (partial response); TE1, treatment effect in target lesion (progressive disease)TE3, treatment effect in target lesion (partial response); TE4a; treatment effect in target lesion (complete response with ablative margin); TE4b, treatment effect in target lesion (complete response without ablative margin). Doxorubicin  399  2  0  Epirubicin  4281  16  19  Mitomycin  1008  4  3  Cisplatin  1416  10  6  SMANCS  203  3  1  Miriplatin  131  0  0  5FU  97  1  1  Interferon were also being treated together with anticancer cytotoxic agents. The scope of embolization was less than one segment for 36.6%, at least one segment but less than one lobe for 40.3%, one lobe or more for 16.6%, and the entire liver for 6.5%. The response assessed at 3 months after treatment initiation was CR in 41.0%, PR in 21.8%, SD in 15.7%, and PD in 21.6% of patients. The corresponding response assessed at 6 months after treatment initiation was 40.1%, 17.3%, 12.1%, and 30.5%.
Systemic chemotherapy
Systemic chemotherapy was carried out in 372 patients with HCC. The response assessed at 3 months after treatment initiation was CR in 3.3%, PR in 13.5%, SD in 21.4%, and PD in 61.9%. Systemic chemotherapy was carried out for 196 patients with ICC. The route of administration was intravenous for 80.6% and oral for 17.9%.
The response assessed at 3 months after treatment initiation was CR in 4.2%, PR in 15.0%, SD in 30.8%, and PD in 50.0% of patients (Table 13) .
Pathology
A pathological diagnosis was obtained for 44.7% of patients with HCC. Of these, 17.6% were made from a biopsy alone, 79.6% from a resected specimen alone, and 2.8% from a biopsy and resected specimen. In addition, 55.3% of patients had no pathological diagnosis, and the rate of diagnosis by biopsy had decreased since previous surveys, and the number of patients without a pathological diagnosis had increased. The histological grade of HCC was well differentiated in 24.9%, moderately differentiated in 62.8%, and poorly differentiated in 11.7% of patients (Table 14) . ICC was well differentiated in 18.5%, moderately differentiated in 58.0%, and poorly differentiated in 20.3% of patients (Table 15 ). Table 16 shows For all parameters, n is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of n. 5FU, fluorouracil; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; SMANCS, styrene maleic acid neocarzinostatin; TE1, treatment effect in target lesion (progressive disease); TE2, treatment effect in target lesion (partial response); TE3, treatment effect in target lesion (partial response); TE4a; treatment effect in target lesion (complete response with ablative margin); TE4b, treatment effect in target lesion (complete response without ablative margin). Table 13 Systemic chemotherapy 5FU, fluorouracil; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; SMANCS, styrene maleic acid neocarzinostatin; TE1, treatment effect in target lesion (progressive disease); TE2, treatment effect in target lesion (partial response); TE3, treatment effect in target lesion (partial response); TE4a; treatment effect in target lesion (complete response with ablative margin); TE4b, treatment effect in target lesion (complete response without ablative margin). For all parameters, n is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of n. A 0 , no necroinflammatory reaction; A 1 , mild necroinflammatory reaction; A 2 , moderate necroinflammatory reaction; A 3 , severe necroinflammatory reaction; proper hepatic artery; b 0 , no invasion of bile duct, b1, branches of the bile duct, but not of second order branches; b 2 , invasion of (or tumor thrombus in) the second order branches of the bile duct; b 3 , invasion of (or tumor thrombus in) the first order branches of the bile duct; b 4 , invasion of (or tumor thrombus in) the common hepatic duct; F 1 , fibrous expansion of portal tract; F 2 , fibrous septa formation, usually incomplete; F 3 , bridging fibrous formation accompanying lobular distortion; fc (À), absence of capsule formation; fc (+), presence of capsule formation; b0, absence of invasion of the bile ducts; b1, invasion of (or tumor thrombus in) the third order or more peripheral; fc-inf (À), absence of cancerous infiltration of the tumor capsule; fc-inf (+), presence of cancerous infiltration of the tumor capsule; im 1 , intrahepatic metastasis within the subsegment in which the principal tumor is located; im 2 , intrahepatic metastasis in two segments; im 3 , intrahepatic metastasis to three or more segments; im s , intrahepatic metastasis within the subsegment in which the principal tumor is located; sf (À), absence of formation of a fibrous septum within the tumor; sf (+), presence of fibrous septum within the tumor; s 0 , absence of invasion of the serosa; s 1 , tumor invasion of the serosa; s 2 , tumor invasion of adjacent organs; s 3 , tumor rupture with intraperitoneal bleeding; va 0 , absence of invasion of the hepatic artery; va 1 , invasion distal to the second order branches of the hepatic artery, but not of the second order branches; va 2 , invasion to the second order branches of the hepatic artery; va 3 , invasion to the left or right hepatic artery, or the im 0 , absence of intrahepatic metastasis; vp 0 , absence of invasion of (or tumor thrombus in) the portal vein; vp 1 , invasion of (or tumor thrombus in) distal to the second order branches of the portal vein, but not of the second order branches; vp 2 , invasion of (or tumor thrombus in) second order branches of the portal vein; vp 3 , invasion of (or tumor thrombus in) first order branches of the portal vein; vp 4 , invasion of (or tumor thrombus in) the main trunk of the portal vein and/or contra-lateral portal vein branch to the primarily involved lobe; vv 0 , absence of invasion of (or tumor thrombus in) the hepatic vein; vv 1 , invasion of (or tumor thrombus in) peripheral branches of the hepatic vein; vv 2 , invasion of (or tumor thrombus in) the right, middle, or left hepatic vein, the inferior right hepatic vein, or the short hepatic vein; vv 3 , invasion of (or tumor thrombus in) the inferior vena cava. details of pathological diagnosis. The non-cancerous part of the liver in patients with HCC was normal in 4.6%, showed chronic hepatitis or fibrosis in 30.8%, and showed cirrhosis in 64.6%; in patients with ICC, it was normal in 66.7%, showed chronic hepatitis or fibrosis in 33.8%, and showed cirrhosis in 0.0%.
Recurrence
Recurrence during the survey period (within 2 years of diagnosis) was reported in 34.3% of patients with HCC. The most frequently performed treatment for intrahepatic recurrence was TACE at 40.2%, followed by local ablation therapy at 24.9%. The most common sites of extrahepatic recurrence were the lungs, bone, and lymph nodes. The most frequently performed treatments For all parameters, n is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of n. b 0 , no invasion of bile duct, b 1 , branches of the bile duct, but not of second order branches; b 2 , invasion of (or tumor thrombus in) the second order branches of the bile duct; b 3 , invasion of (or tumor thrombus in) the first order branches of the bile duct; b 4 , invasion of (or tumor thrombus in) the common hepatic duct; fc (À), absence of capsule formation; fc (+), presence of capsule formation; fc-inf (À), absence of cancerous infiltration of the tumor capsule; fc-inf (+), presence of cancerous infiltration of the tumor capsule; im 0 , absence of intrahepatic metastasis; im 1 , intrahepatic metastasis within the subsegment in which the principal tumor is located; im 2 , intrahepatic metastasis in two segments; im 3 , intrahepatic metastasis to three or more segments; im s , intrahepatic metastasis within the subsegment in which the principal tumor is located; sf (À), absence of formation of a fibrous septum within the tumor; sf (+), presence of fibrous septum within the tumor; s 0 , absence of invasion of the serosa; s 1 , tumor invasion of the serosa; s 2 , tumor invasion of adjacent organs; s 3 ,tumor rupture with intraperitoneal bleeding; va 0 , absence of invasion of the hepatic artery; va 1 , invasion distal to the second order branches of the hepatic artery, but not of the second order branches; va 2 , invasion to the second order branches of the hepatic artery; va 3 , invasion to the left or right hepatic artery, or the proper hepatic artery; vp 0 , absence of invasion of (or tumor thrombus in) the portal vein; vp1 , invasion of (or tumor thrombus in) distal to the second order branches of the portal vein, but not of the second order branches; vp 2 , invasion of (or tumor thrombus in) second order branches of the portal vein; vp 3 , invasion of (or tumor thrombus in) first order branches of the portal vein; vp 4 , invasion of (or tumor thrombus in) the main trunk of the portal vein and/ or contra-lateral portal vein branch to the primarily involved lobe; vv 0 , absence of invasion of (or tumor thrombus in) the hepatic vein; vv 1 , invasion of (or tumor thrombus in) peripheral branches of the hepatic vein; vv 2 , invasion of (or tumor thrombus in) the right, middle, or left hepatic vein, the inferior right hepatic vein, or the short hepatic vein; vv 3 , invasion of (or tumor thrombus in) the inferior vena cava. for distant recurrence were systemic chemotherapy (total includes both cytotoxic chemotherapy agents and molecularly targeted agents), radiotherapy, and surgery, in that order.
Autopsy
Autopsies were carried out for a total of 91 patients with primary liver cancer. HCC was found in 85 patients. The rate of cirrhosis among autopsied patients with HCC was 64.6%, and rates of invasion of the portal vein, hepatic veins, and bile duct were 54.5%, 40.4%, and 18.7%, respectively. Extrahepatic spread was most frequently detected in the lungs (31.5%), lymph nodes (19.0%), and bone (16.7%). For ICC, the most common sites of extrahepatic spread were the intraperitoneal organs and the lungs, and the rate of lymph node metastasis was 75.0% (Table 17 ).
CUMULATIVE SURVIVAL RATES
Cumulative survival rates from the 15th to 20th surveys (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) C UMULATIVE SURVIVAL RATES were calculated for patients with HCC, ICC, and combined HCC and AFP, α-fetoprotein; LCSGJ, Liver Cancer Study Group of Japan; TNM, tumor-node-metastasis; Vp 0 , absence of invasion of (or tumor thrombus in) the portal vein; Vp 1 , invasion of (or tumor thrombus in) distal to the second order branches of the portal vein, but not of the second order branches; Vp 2 , invasion of (or tumor thrombus in) second order branches of the portal vein; Vp 3 , invasion of (or tumor thrombus in) first order branches of the portal vein; vp 4 , invasion of (or tumor thrombus in) the main trunk of the portal vein and/or contra-lateral portal vein branch to the primarily involved lobe.
ICC who were newly registered in the surveys from 1998 to 2009, and whose final outcome was survival or death (excluding unknown).
Cumulative survival rates for hepatocellular carcinoma (Table 18 ; Fig. 1 ).
• Cumulative survival rates for resected HCC: median overall survival (OS) for all patients with a Child-Pugh grade A who underwent resection was 96.89 months, and 5-and 10-year survival rates were 65.8% and 44.0% (Table 19 ; Fig. 2 ). The TNM stage was well correlated with survival (Table 19 ; Fig. 3 ). Maximum tumor diameter, number of tumors, and extent of portal invasion (Fig. 4) , as well as αfetoprotein ( Fig. 5 ), were also well correlated with survival (Table 19 ).
• Cumulative survival rates for HCC treated with local ablation therapy: median OS for patients with a Child-Pugh grade A who underwent local ablation therapy was 81.41 months, and 5and 10-year survival rates were 63.8% and 23.2% (Fig. 6 ). The number of tumors and tumor Fig. 7 ). The number of tumors was well correlated with survival rate after TACE (Table 21 ; Fig. 8 ). Tables 22 and 23 17.02 months and 22.6%/12.2% for period 3 (n = 4552), and 20.6 months and 30.9%/10.7% for period 4 (n = 3184). Survival has gradually improved over the years, although not as dramatically as for HCC (Table 24 ; Fig. 10 ).
Cumulative survival rates for intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma
Conclusion: Primary liver cancer is the fifth most common cause of cancer death in Japan after lung cancer, colorectal cancer, gastric cancer, and pancreatic cancer. 77 The number of deaths from HCC peaked at 34 510 in 2004, and has continued to decrease gradually every year since. Nevertheless, it is reported that >28 000 people still die from HCC each year. Approximately 37.5% of the patients with primary liver cancer registered in the 20th Nationwide Follow-up Survey of Primary Liver Cancer in Japan were newly registered.
Compared with the 19th survey, the population of patients with HCC in this survey was older at the time of clinical diagnosis, included more female patients, had smaller tumor diameters, and more frequently received radiofrequency ablation as local ablation therapy. Calculation of the median OS and cumulative survival rates for patients newly registered in the four time periods between 1978 and 2009 revealed marked improvement in survival rates for HCC, which can be attributed to advances in early diagnosis and treatment. The OS of HCC in Japan is number 1 in the world according to the comparison with the published data from other countries worldwide. 62, 78 We believe that the large set of data from registered patients analyzed in this follow-up survey will advance the research and treatment outcome of primary liver cancer.
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